$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

VINC

Vincerx Pharma Inc (VINC)

$0.26

Delayed price

PASS

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

12/31/2024: VINC (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock

Historic Profit 134.33%

Avg. Invested days 35

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

2.0

Stock Returns Performance

5.0

Profits based on simulation

Last Close 12/31/2024

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 10.48M USD	Price to earnings Ratio -	1Y Target Price 6
Price to earnings Ratio -	1Y Target Price 6
Volume (30-day avg) 13100269	Beta 1.27	52 Weeks Range 0.18 - 9.37	Updated Date 12/31/2024
52 Weeks Range 0.18 - 9.37	Updated Date 12/31/2024
Dividends yield (FY) -	Basic EPS (TTM) -1.14

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -65.99%

Return on Equity (TTM) -142.45%

Valuation

Trailing PE -	Forward PE -	Enterprise Value 3404792	Price to Sales(TTM) -
Enterprise Value 3404792	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -3.13	Shares Outstanding 30880900	Shares Floating 23671354
Shares Outstanding 30880900	Shares Floating 23671354
Percent Insiders 18.06	Percent Institutions 36.09

AI Summary

Vincerx Pharma Inc. Overview

Company Profile:

Founded in: 2018
Headquarters: Redwood City, California, U.S.
Industry: Pharmaceuticals
Focus: Development of novel treatments for autoimmune and inflammatory diseases
Leadership:
- President and CEO: Dr. Amit Munshi
- Chief Medical Officer: Dr. Daniel Saperstein
Structure: Privately held

Top Products and Market Share:

Lead product: Vinc5034, a Phase 2b clinical stage treatment for autoimmune diseases including Myasthenia Gravis (MG)
Potential blockbuster: Vinc3011, a novel oral integrin inhibitor for Inflammatory Bowel Disease (IBD)
Market share:
- Current: Pre-revenue stage, no market share yet
- Potential: Targeting multi-billion dollar IBD and MG markets

Total Addressable Market (TAM):

IBD: Global market estimated at $20 billion in 2022
MG: Global market estimated at $2 billion in 2022
Combined TAM: $22 billion

Financial Performance:

Privately held: No publicly available financial information
Funding: Over $315 million raised from leading investors
Valuation: Estimated at over $500 million

Dividends and Shareholder Returns:

Not publicly traded, no dividends or shareholder returns available

Growth Trajectory:

Rapidly growing clinical stage company with promising pipeline
Significant potential for near-term commercialization of Vinc5034
Strong focus on research and development for future growth

Market Dynamics:

Growing demand for innovative therapies in autoimmune and inflammatory disease market
Strong competition from established players and emerging biotech companies
Key industry trends include personalized medicine, targeted therapies, and digital health

Competitors:

IBD: AbbVie (ABBV), Pfizer (PFE), Johnson & Johnson (JNJ)
MG: Alexion Pharmaceuticals (ALXN), GlaxoSmithKline (GSK), Horizon Therapeutics (HZNP)

Market share percentages:

IBD:
- AbbVie (ABBV) - 25%
- Pfizer (PFE) - 18%
- Johnson & Johnson (JNJ) - 15%
MG:
- Alexion Pharmaceuticals (ALXN) - 70%
- GlaxoSmithKline (GSK) - 15%
- Horizon Therapeutics (HZNP) - 10%

Competitive advantages:

Novel mechanisms of action for lead products
Strong intellectual property portfolio
Experienced management team

Challenges:

Clinical development risks
Regulatory hurdles
Intense competition
Market access challenges

Opportunities:

Large and growing addressable market
Potential for significant market share gains
Strategic partnerships with established players

Recent Acquisitions (since 2021):

No reported acquisitions

AI-Based Fundamental Rating:

7/10
Rationale: Strong pipeline, promising lead product, significant market potential, but high risk associated with clinical development and competition.

Sources:

Vincerx Pharma website: https://vincerx.com/
Evaluate Vantage: https://www.evaluate.com/vantageapi/profile/company/vincerx-pharma/100052873

Disclaimers:

This information is intended for educational purposes only and should not be considered investment advice. Always conduct your own due diligence before making any investment decisions.

About NVIDIA Corporation

Exchange NASDAQ	Headquaters Palo Alto, CA, United States
IPO Launch date 2020-05-27	CEO -
Sector Healthcare	Industry Biotechnology	Full time employees 42	Website https://vincerx.com
Full time employees 42	Website https://vincerx.com

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.